1.
Medication adherence: A call for action
by Bosworth, Hayden B., PhD
The American heart journal, 2011, Vol.162 (3), p.412-424
2.
'A necessary evil': associations with taking medication and their relationship with medication adherence
by Kleppe, Mieke
Psychology, health & medicine, 2017, Vol.22 (10), p.1217-1223
3.
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
by Verma, Subodh
Diabetologia, 2018, Vol.61 (10), p.2108-2117
4.
Eph Receptors and Ephrins: Therapeutic Opportunities
by Barquilla, Antonio
Annual review of pharmacology and toxicology, 2015, Vol.55 (1), p.465-487
5.
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
by Böhm, Michael, Prof
The Lancet (British edition), 2017, Vol.389 (10085), p.2226-2237
6.
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
by Marso, Steven P., MD
The American heart journal, 2013, Vol.166 (5), p.823-830.e5
7.
MicroRNAs in cardiovascular disease: an introduction for clinicians
by Romaine, Simon P R
Heart, 2015, Vol.101 (12), p.921-928
8.
The Nonskeletal Effects of Vitamin D: An Endocrine Society Scientific Statement
by Rosen, Clifford J
Endocrine reviews, 2012, Vol.33 (3), p.456-492
9.
A systematic review of statin-induced muscle problems in clinical trials
by Ganga, Harsha V., MD
The American heart journal, 2014, Vol.168 (1), p.6-15
10.
Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance
by Fleg, Jerome L
Hypertension (Dallas, Tex. 1979), 2016, Vol.68 (4), p.888-895
11.
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study da...
by Khatib, Rasha, PhD
The Lancet (British edition), 2016, Vol.387 (10013), p.61-69
12.
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
by Kiyosue, Arihiro, MD, PhD
The American journal of cardiology, 2016, Vol.117 (1), p.40-47
13.
Medication Adherence: WHO Cares?
by Brown, Marie T., MD
Mayo Clinic proceedings, 2011, Vol.86 (4), p.304-314
14.
Gender and racial disparities in adherence to statin therapy: A meta-analysis
by Lewey, Jennifer, MD
The American heart journal, 2013, Vol.165 (5), p.665-678.e1
15.
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary...
by Athyros, Vasilios G, MD
The Lancet (British edition), 2010, Vol.376 (9756), p.1916-1922
16.
Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis
by Elmariah, Sammy, MD
The Lancet (British edition), 2015, Vol.385 (9970), p.792-798
17.
Astaxanthin: A Novel Potential Treatment for Oxidative Stress and Inflammation in Cardiovascular Disease
by Pashkow, Fredric J., MD
The American journal of cardiology, 2008, Vol.101 (10), p.S58-S68
18.
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
by Baigent, Colin
The Lancet (British edition), 2009, Vol.373 (9678), p.1849-1860
19.
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPRO...
by Blazing, Michael A., MD
The American heart journal, 2014, Vol.168 (2), p.205-212.e1
20.
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
by Nathan, David M
Diabetologia, 2019, Vol.62 (8), p.1319-1328
